2-[((3,4-二氢-4-氧代-3,5-二苯基噻吩并[2,3-d]嘧啶-2-基)硫代]乙酸酰肼 | 312946-37-5

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 2-[((3,4-二氢-4-氧代-3,5-二苯基噻吩并[2,3-d]嘧啶-2-基)硫代]乙酸酰肼
• 英文名称: LDN-27219
• 英文别名: (4-oxo-3,5-diphenyl-3,4-dihydro-thieno[2,3-d]pyrimidin-2-ylsulfanyl)acetic acid hydrazide；2-(4-Oxo-3,5-diphenylthieno[2,3-d]pyrimidin-2-yl)sulfanylacetohydrazide
• CAS: 312946-37-5
• 化学式: C₂₀H₁₆N₄O₂S₂
• mdl: MFCD01943209
• 分子量: 408.505
• InChiKey: WLBUICQBNZXIDJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.45±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：可溶15mg/mL，澄清

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  141
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氨基-4-苯基噻吩-3-羧酸乙酯 在 吡啶 、 sodium methylate 、 potassium carbonate 、 肼 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-[((3,4-二氢-4-氧代-3,5-二苯基噻吩并[2,3-d]嘧啶-2-基)硫代]乙酸酰肼
  参考文献：
  名称：

  Structure–activity relationship study of novel tissue transglutaminase inhibitors

  摘要：

  Thieno[2,3-d]pyrimidin-4-one acylhydrazide derivatives were discovered as moderately potent inhibitors of TGase 2 (tissue transglutaminase) utilizing a fluorescence-based assay that measured TGase 2 catalyzed incorporation of the dansylated Lys derivative alpha-N-Boc-Lys-CH2-CH2-dansyl into the protein substrate N,N-dimethylated-casein. A SAR study revealed that the acylhydrazide thioether side-chain and the thiophene ring were critical to inhibitory activity. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.005

文献信息

• Tissue transglutaminase inhibitors
  申请人：Stein L. Ross

  公开号：US20060183759A1

  公开（公告）日：2006-08-17

  The present invention provides novel compounds and methods useful for treating transglutaminase associated disorders such as celiac spru, Alzheimer's disease and Huntington's disease. Certain compounds of the invention are tissue transglutaminase inhibitors that comprise thiophene moieties. Methods of the invention include treatment of transglutaminase associated disorders with inhibitors of transglutaminase.

  本发明提供了一种治疗转酰胺酶相关疾病的新化合物和方法，例如腹泻性脆皮病、阿尔茨海默病和亨廷顿病。本发明的某些化合物是组织转酰胺酶抑制剂，包括噻吩基团。本发明的方法包括使用转酰胺酶抑制剂治疗转酰胺酶相关疾病。
• FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY
  申请人：ETH Zürich

  公开号：EP3257862A1

  公开（公告）日：2017-12-20

  The present invention is directed to a composition comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic agent, a nucleic acid encoding a fusion polypeptide comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic polypeptide agent as well as a corresponding recombinant vector and host cell comprising such a nucleic acid and preferably expressing said fusion polypeptide. The invention also relates to a kit of parts comprising at least one fibronectin binding polypeptide (FnBP), at least one diagnostic or therapeutic agent, and optionally one or more chemical agents for linking the fibronectin binding polypeptide (FnBP) to the diagnostic or therapeutic agent. In addition, the present invention intends said composition, nucleic acid, vector, host cell and kit for use in the therapeutic or prophylactic treatment of a disease, preferably a disease associated with abnormal fibronectin accumulation such as cancer and fibrosis.

  本发明涉及一种组合物，该组合物包含至少一种与至少一种诊断或治疗剂连接的纤连蛋白结合多肽（FnBP），一种编码融合多肽的核酸，该融合多肽包含至少一种与至少一种诊断或治疗多肽剂连接的纤连蛋白结合多肽（FnBP），以及相应的重组载体和宿主细胞，该重组载体和宿主细胞包含这样的核酸，最好表达所述融合多肽。本发明还涉及一种成套部件，包括至少一种纤连蛋白结合多肽（FnBP）、至少一种诊断或治疗剂，以及可选的一种或多种用于将纤连蛋白结合多肽（FnBP）与诊断或治疗剂连接的化学制剂。此外，本发明打算将所述组合物、核酸、载体、宿主细胞和试剂盒用于治疗或预防疾病，最好是与纤维连接蛋白异常积累有关的疾病，如癌症和纤维化。
• TISSUE TRANSGLUTAMINASE MODULATORS FOR MEDICINAL USE
  申请人：Aarhus Universitet

  公开号：EP3607948A1

  公开（公告）日：2020-02-12

  The present invention relates to a compound which is a modulator of tissue transglutaminase (TG2) for use in the treatment of endothelial dysfunction and diseases related thereto or resulting therefrom. In particular the present invention relates to the compound LDN-27219 (Formula II herein) and derivatives thereof for use in the treatment of diseases resulting from endothelial dysfunction, especially in association with aging and diabetic subjects.

  本发明涉及一种化合物，它是组织转谷氨酰胺酶（TG2）的调节剂，用于治疗内皮功能障碍和与此相关或由此引起的疾病。特别是本发明涉及化合物LDN-27219（本文中的式II）及其衍生物，用于治疗内皮功能障碍导致的疾病，特别是与衰老和糖尿病受试者有关的疾病。
• WO2006/60702
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] FIBRONECTIN-BINDING PEPTIDES FOR USE IN TUMOR OR FIBROSIS DIAGNOSIS AND THERAPY<br/>[FR] PEPTIDES DE LIAISON À LA FIBRONECTINE UTILISÉS POUR LE DIAGNOSTIC ET LE TRAITEMENT DES TUMEURS OU DES FIBROSES
  申请人：ETH ZUERICH

  公开号：WO2017216223A1

  公开（公告）日：2017-12-21

  The present invention is directed to a composition comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic agent, a nucleic acid encoding a fusion polypeptide comprising at least one fibronectin binding polypeptide (FnBP) linked to at least one diagnostic or therapeutic polypeptide agent as well as a corresponding recombinant vector and host cell comprising such a nucleic acid and preferably expressing said fusion polypeptide. The invention also relates to a kit of parts comprising at least one fibronectin binding polypeptide (FnBP), at least one diagnostic or therapeutic agent, and optionally one or more chemical agents for linking the fibronectin binding polypeptide (FnBP) to the diagnostic or therapeutic agent. In addition, the present invention intends said composition, nucleic acid, vector, host cell and kit for use in the therapeutic or prophylactic treatment of a disease, preferably a disease associated with abnormal fibronectin accumulation such as cancer, fibrosis or immune diseases.